The 117th Annual Meeting of the American Association for Cancer Research (AACR) will be held in San Diego, USA, from April 17 to April 22, 2026. As the world's earliest established and largest cancer research organization, the AACR Annual Meeting focuses on key scientific topics spanning from bench to bedside. Research findings presented at the conference typically represent the cutting-edge breakthrough directions of global cancer research.

At this year's conference, Juncell Therapeutics will present a long-term stability study on Tumor-Infiltrating Lymphocyte (TIL) seed cells and final drug products. The study results validated the robustness and feasibility of the "cryopreservation-expansion" process. By separating tumor tissue collection from TIL treatment administration, this time-phased process substantially enhances the accessibility and clinical practicality of TIL therapy.

Abstract Number: #3699

Abstract Title: The "Preservation & Expansion" Process: A Key Milestone for Enhancing Accessibility of Autologous Tumor-Infiltrating Lymphocyte Therapy by  Enabling Long-Term Cryopreservation of Seed Cells

Research Institution: Juncell Therapeutics‌

Poster Presentation Time: Apr.17 - Apr.22, 2026

Autologous tumor-infiltrating lymphocyte (TIL) therapy has demonstrated remarkable clinical efficacy in the treatment of advanced solid tumors; however, its widespread application remains constrained by the requirement for timely tumor resection. Many patients with progressive disease are unable to undergo surgical tissue harvesting, resulting in missed opportunities for TIL treatment.

Leveraging Juncell Therapeutics independently developed DeepTIL™ cell expansion platform, the proprietary segmented manufacturing process achieves a key technological innovation and addresses two major challenges at once. First, tumor tissue is collected during the initial surgery, from which TIL seed cells are isolated and cryopreserved. Upon tumor recurrence, the cryopreserved cells can be rapidly recovered, expanded and reinfused, fundamentally resolving the clinical dilemma of difficult re-harvesting after disease relapse. Second, empowered by the proprietary platform, the technical bottleneck of TIL seed cell cryopreservation has been overcome, effectively solving insufficient viability recovery of cells before cryopreservation. This avoids massive cell death and subsequent failure of rapid cell expansion caused by inadequate viability restoration.

In the research presented at the AACR Annual Meeting, Juncell Therapeutics conducted a systematic evaluation across multiple dimensions, including cell recovery viability, proportions of various cell subsets, cell exhaustion status, CD8⁺/CD4⁺ ratio, expansion capacity, and ex vivo tumor-killing capability. The results confirmed that cryopreservation for up to two years exerts no significant impact on the viability, proliferative capacity, or tumor-killing functions of TIL seed cells and final cell products. The strategy of early tumor tissue harvesting and the innovative cryopreservation-expansion process are poised to become critical drivers for improving the accessibility of TIL therapy.